Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 6:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Multimodal treatment Clear all
Completed Phase 1 Interventional

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment

NCT03335540
View directory record Official record
Conditions
Advanced Cancer
Interventions
Nivolumab, Relatlimab, Cabiralizumab, Ipilimumab, IDO1 Inhibitor, Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Sep 27, 2026, 6:02 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Oral Curcumin Supplementation in Dry Age-related Macular Degeneration (AMD) Patients

NCT04590196
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Longvida curcumin, placebo
Drug · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 27, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Results available

Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

NCT02526017
View directory record Official record
Conditions
Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Renal Cell Carcinoma, Malignant Glioma, Non-small Cell Lung Cancer
Interventions
Cabiralizumab, Nivolumab
Biological
Lead sponsor
Five Prime Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
39
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Sep 27, 2026, 6:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

NCT05867420
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ASKG915, Paclitaxel + Bevacizumab, Fruquintinib, Docetaxel
Biological · Drug
Lead sponsor
AskGene Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 27, 2026, 6:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

ADASUVE-Lorazepam Drug-Drug Interaction

NCT01877642
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lorazepam 1 mg IM, Inhaled loxapine 10 mg, Inhaled Placebo, Placebo IM
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 27, 2026, 6:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors

NCT07095868
View directory record Official record
Conditions
Selected Types of Solid Tumor
Interventions
EVM14, Pembrolizumab
Biological · Combination Product
Lead sponsor
Everest Medicines (Beijing) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
New York, New York • Houston, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 27, 2026, 6:02 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Combining Behavioral and Pharmacologic Therapy for Complex Insomnia in Veterans With PTSD

NCT03937713
View directory record Official record
Conditions
Complex Insomnia
Interventions
eszopiclone, Brief behavioral therapy for insomnia
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 27, 2026, 6:02 AM EDT
Completed Phase 4 Interventional Results available

Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis

NCT00028262
View directory record Official record
Conditions
Infantile Neronal Ceroid Lipofuscinosis
Interventions
Cystagon
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
6 Months to 3 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 27, 2026, 6:02 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

NCT04058353
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA, TEZ/IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 27, 2026, 6:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

NCT01218477
View directory record Official record
Conditions
Leukemia
Interventions
Dasatinib, BMS-833923
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Sep 27, 2026, 6:02 AM EDT
Active, not recruiting No phase listed Observational

MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

NCT05739136
View directory record Official record
Conditions
Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk
Interventions
Relugolix + Estradiol + Norethindrone Acetate
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Sep 27, 2026, 6:02 AM EDT
Recruiting Not applicable Interventional

Vision Rehabilitation Training With Multimodal Feedback in Central Vision Loss

NCT07577219
View directory record Official record
Conditions
Low Vision, Central Visual Impairment, Macular Degeneration
Interventions
eccentric viewing training with biofeedback
Behavioral
Lead sponsor
New England College of Optometry
Other
Eligibility
14 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 27, 2026, 6:02 AM EDT
Recruiting Phase 3 Interventional

Sleep Quality and the Efficacy of a Multimodal Sleep Pathway in Hospitalized Orthopedic Trauma Patients

NCT07336277
View directory record Official record
Conditions
Orthopedic Trauma, Sleep Quality
Interventions
Standard Postoperative Care, Zolpidem, Melatonin, Sleep Hygiene Education, Actigraph GT3X-BT Actigraph
Other · Drug · Dietary Supplement + 2 more
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 27, 2026, 6:02 AM EDT
Completed Phase 2 Interventional Results available

Risperidone for the Treatment of Huntington's Disease Involuntary Movements

NCT04201834
View directory record Official record
Conditions
Huntington Disease, Chorea
Interventions
Risperidone, BioStamp nPoint device
Drug · Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 27, 2026, 6:02 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers

NCT07811297
View directory record Official record
Conditions
Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
Interventions
AL58805, AL3818, Temozolomide (TMZ), CCNU
Drug
Lead sponsor
Advenchen Pharmaceuticals, LLC.
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 27, 2026, 6:02 AM EDT
Completed Phase 2 Interventional Results available

Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma

NCT01572480
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Revlimid, Dexamethasone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 27, 2026, 6:02 AM EDT
Enrolling by invitation Phase 4 Interventional

Efficacy And Safety Of Tramadol And Oxycodone Versus Oxycodone Monotherapy For Pain Control After Primary Total Knee And Total Hip Arthroplasty

NCT07153003
View directory record Official record
Conditions
Post Operative Pain
Interventions
Oxycodone, Tramadol and Oxycodone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 27, 2026, 6:02 AM EDT
Completed Not applicable Interventional

Prolonged Multimodal Analgesia for Post-Discharge Pain Control After Primary Total Hip Arthroplasty

NCT03358888
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Multi-modal with as needed opioids, Multi-modal with one week of opioids offered, Standard of Care
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Sep 27, 2026, 6:02 AM EDT
Terminated Phase 3 Interventional Results available

A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy

NCT03447262
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-659/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
48
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Sep 27, 2026, 6:02 AM EDT
Recruiting Not applicable Interventional

Intervention for Communication Quality of Life in Primary Progressive Aphasia

NCT07219680
View directory record Official record
Conditions
Primary Progressive Aphasia(PPA), Semantic Dementia, Logopenic Progressive Aphasia (LPA), Nonfluent Aphasia, Progressive, Progressive Aphasia, Semantic Variant Primary Progressive Aphasia (svPPA), Semantic Aphasia, Logopenic Variant Primary Progressive Aphasia, Logopenic Variant of Primary Progressive Aphasia (LPA), Logopenic Progressive Aphasia, Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Nonfluent Progressive Aphasia
Interventions
Multicomponent Lexical Retrieval Cascade Training, Multicomponent Video Implemented Script Training in Aphasia
Behavioral
Lead sponsor
Maya Henry
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 27, 2026, 6:02 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

NCT02441686
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Lenalidomide, Dexamethasone, Stem Cell Mobilization, Autologous Stem Cell Transplant
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
8
States / cities
Denver, Colorado • Brewer, Maine • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 27, 2026, 6:02 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

NCT05450692
View directory record Official record
Conditions
Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions
Ceralasertib, Durvalumab, Docetaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
27
States / cities
Mobile, Alabama • Chandler, Arizona • Los Alamitos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 27, 2026, 6:02 AM EDT
Terminated Phase 1 Interventional Results available

AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

NCT05209152
View directory record Official record
Conditions
Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Interventions
AMG 176, Azacitidine
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 27, 2026, 6:02 AM EDT
Terminated Phase 1 Interventional Results available

A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

NCT03582033
View directory record Official record
Conditions
Multiple Myeloma
Interventions
SEA-BCMA, dexamethasone, pomalidomide
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
13
States / cities
Palo Alto, California • Aurora, Colorado • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Sep 27, 2026, 6:02 AM EDT